Indian Pharma Market Sees Pick Up In December After A Subdued November: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian Pharma Market growth increased to 8.5% YoY in December 2020 versus 1% YoY in November 2020.
Gastro/Cardiac/ vitamins-minerals-nutrients therapies exhibited a YoY growth of 16.2%/14.9%/14%.
Anti-Infectives therapy is back on the growth path, with 5.2% YoY growth in Dec-20 versus flat sales YoY in Nov-20.
Respiratory sales remained in a downtrend with 8.7% YoY decline in Dec-20.
National List of Essential Medicines (approximately 17% of IPM) grew 6.3%% YoY. Non-NLEM (~83% of IPM) grew at 9%.
On a moving annual turnover basis, industry growth came in at 3.1% YoY.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.